Pacira BioSciences (STU:82P) Construction In Progress: €9.5 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:82P Pacira BioSciences Inc STU:82P
75 GF Score
Price €22.80
GF Value €25.82
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Pacira BioSciences Construction In Progress?

Pacira BioSciences STU:82P -2.56% 75 Construction In Progress is €9.5 Mil as of Mar. 2026. GuruFocus rates STU:82P with a GF Score™ of 75/100 and a GF Value™ of €25.82 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Pacira BioSciences's quarterly construction in progress declined from Sep. 2025 (€10.0 Mil) to Dec. 2025 (€8.1 Mil) but then increased from Dec. 2025 (€8.1 Mil) to Mar. 2026 (€9.5 Mil).

Pacira BioSciences's annual construction in progress declined from Dec. 2023 (€97.1 Mil) to Dec. 2024 (€26.7 Mil) and declined from Dec. 2024 (€26.7 Mil) to Dec. 2025 (€8.1 Mil).

Pacira BioSciences Construction In Progress Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Construction In Progress Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.29 97.45 97.12 26.74 8.10

Pacira BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.24 8.35 10.04 8.10 9.47
STU:82P
75GF Score
Pacira BioSciences Inc STU:82P
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €9.5 Mil mean?
Pacira BioSciences (STU:82P) has a Construction In Progress of €9.5 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' Construction In Progress too high?
Pacira BioSciences' current Construction In Progress is €9.5 Mil. Overall, Pacira BioSciences has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Construction In Progress compare to ALVO and BIOA?
Pacira BioSciences' Construction In Progress of €9.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Construction In Progress is €9.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (STU:82P) is currently considered Modestly Undervalued. The stock's GF Value™ is €25.82, compared to a current price of €22.80 — trading 11.7% below its estimated fair value. The current Construction In Progress is €9.5 Mil. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Pacira BioSciences (STU:82P), the current Construction In Progress is €9.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (STU:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €22.80 is trading 11.7% below its estimated GF Value™ of €25.82. GuruFocus considers Pacira BioSciences to be Modestly Undervalued.

Key valuation signals for STU:82P:

  • Construction In Progress: €9.5 Mil
  • GF Value™: €25.82 vs. price of €22.80 (11.7% below fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the STU:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Other Exchanges PCRX:USA
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score

Get the complete analysis for STU:82P

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.80
Price
€25.82
GF Value